Alternating Peptides for Neurological Diseases

AltPep is pioneering a novel approach to the diagnosis and treatment of amyloid diseases, particularly focusing on Alzheimer’s and Parkinson’s diseases. Central to their strategy is the identification and targeting of α-sheet structures, which are critical features of toxic oligomers that trigger these diseases. By developing a highly-selective platform that utilizes custom-designed synthetic peptides, AltPep aims to detect and neutralize these toxic oligomers early in the disease progression. This innovative methodology is designed to facilitate early intervention, potentially altering the course of these debilitating conditions before significant symptoms manifest.

The company's pipeline includes two main components: SOBIN Therapeutics and SOBA Diagnostics. SOBIN Therapeutics is being developed to work in conjunction with early detection methods to target and neutralize α-sheet toxic soluble oligomers associated with amyloid diseases. Meanwhile, SOBA Diagnostics focuses on creating highly sensitive blood tests to aid in the early detection of these diseases. Both initiatives are crucial in addressing the urgent need for early diagnosis and treatment, as current therapies primarily provide symptomatic relief and often fail to address the underlying causes of the diseases. AltPep's commitment to transforming the landscape of amyloid disease management holds promise for millions affected globally.

United States

AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach.

Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.

AltPep

Company Details